Luminary licenses TcBuster CAR T tech from Bio-Techne Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the manufacturing of gene-modified cell therapies.Read More
Sirion Biotech, Sanofi to improve AAV capsids Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors for the development of effective gene therapies.Read More
Thermo Fisher acquires cell-sorting technology from Propel Labs Thermo Fisher Scientific acquired cell-sorting technology assets from Propel Labs, a wholly owned subsidiary of SIDIS. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher's Biosciences business. Propel Labs will continue to operate as a separate entity, according to a press release.Read More
AI uncovers the genome's hidden regulatory code A neural network trained on high-resolution maps of protein-DNA interactions can uncover how these sequences are organized to regulate genes, revealing a hidden regulatory code. Findings from use of the artificial intelligence (AI) model were published in Nature Genetics on February 18.Read More
Selecta, AskBio start gene therapy ImmTor trial Selecta Biosciences and Asklepios BioPharmaceutical (AskBio) have initiated a phase I clinical trial to evaluate the safety and preliminary efficacy of ImmTor in gene therapy.Read More
Proteomics helps researchers pick the best anti-SARS-CoV-2 nanobodies A new high-throughput proteomics-based strategy to identify tiny antibody fragments -- called nanobodies -- may provide an efficient and effective method for developing therapeutics against the deadly SARS-CoV-2 virus -- including variants. The findings were published in Cell Systems on February 15.Read More